Ayvakyt (avapritinib) receives European Commission approval as the first and only treatment for indolent systemic mastocytosis
Blueprint Medicines Corporation has announced the European Commission has approved Ayvakyt (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment
Ayvakyt is the first and only approved therapy for people living with ISM in Europe.
Systemic mastocytosis (SM) is a rare hematologic disorder that can lead to a range of debilitating symptoms with a significant impact on patients' quality of life. The majority of patients living with SM have ISM, and there are approximately 40,000 people living with ISM in the European Union. Ayvakyt was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins